Aktuellt
SENASTE
Redeye comments on Fluoguide’s Q2 2022 report, and we judge that the company is laser-focused on delivering catalysts that will bring FG001 into the limelight in the coming six to 12 months. Further, the company provided a general update on FG001’s clinical development timeline and announced head and neck cancer as a new indication. We fine-tune our estimates.
LÄS MER
